Annexin Pharmaceuticals AB (ANNX) — Cash Flow-to-Debt Ratio
Latest as of March 2026:
-1.86x
Annexin Pharmaceuticals AB (ANNX) has a Cash Flow-to-Debt Ratio of -1.86x as of March 2026, meaning its operating cash flow of Skr-10.33 Million could theoretically repay -2% of its total liabilities (Skr5.56 Million) in one year. See Annexin Pharmaceuticals AB (ANNX) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-1.86x
Operating CF / Total Liabilities
Operating Cash Flow
Skr-10.33 Million
SEK
Total Liabilities
Skr5.56 Million
SEK
Data as of
Mar 2026
Most recent filing
Annexin Pharmaceuticals AB Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Annexin Pharmaceuticals AB across 11 annual periods. For the full cash flow conversion analysis, see how efficiently does Annexin Pharmaceuticals AB generate cash.
Annual Cash Flow-to-Debt Ratio for Annexin Pharmaceuticals AB (2015–2025)
Year-by-year debt coverage analysis for Annexin Pharmaceuticals AB.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -7.07x | Skr-36.92 Million | Skr5.22 Million | ▲ +25.1% |
| 2024 | -9.44x | Skr-50.23 Million | Skr5.32 Million | ▼ -72.8% |
| 2023 | -5.46x | Skr-43.40 Million | Skr7.95 Million | ▲ +13.4% |
| 2022 | -6.31x | Skr-41.16 Million | Skr6.53 Million | ▲ +15.1% |
| 2021 | -7.43x | Skr-45.02 Million | Skr6.06 Million | ▲ +14.3% |
| 2020 | -8.67x | Skr-39.20 Million | Skr4.52 Million | ▼ -53.3% |
| 2019 | -5.66x | Skr-25.73 Million | Skr4.55 Million | ▼ -22.8% |
| 2018 | -4.61x | Skr-28.50 Million | Skr6.19 Million | ▲ +24.5% |
| 2017 | -6.10x | Skr-39.08 Million | Skr6.41 Million | ▼ -383.3% |
| 2016 | -1.26x | Skr-9.95 Million | Skr7.88 Million | ▲ +17.4% |
| 2015 | -1.53x | Skr-5.01 Million | Skr3.28 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.